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Abstract
Background: Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic
stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased availability of
unrelated donors together with the significant reduction in transplant-related mortality in recent years have opened
the possibility for transplantation to a larger number of patients with PRF-AML. Moreover, transplant from unrelated
donors may be associated with stronger graft-mediated anti-leukemic effect in comparison to transplantations from
HLA-matched sibling donor, which may be of importance in the setting of PRF-AML.
Methods: The current study aimed to address the issue of HSCT for PRF-AML and to compare the outcomes of HSCT
from matched sibling donors (n = 660) versus unrelated donors (n = 381), for patients with PRF-AML between 2000 and
2013. The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models
were used where appropriate.
Results: HSCT provide patients with PRF-AML a 2-year leukemia-free survival and overall survival of about 25 and 30%,
respectively. In multivariate analysis, two predictive factors, cytogenetics and time from diagnosis to transplant, were
associated with lower leukemia-free survival, whereas Karnofsky performance status at transplant ≥90% was associated
with better leukemia-free survival (LFS). Concerning relapse incidence, cytogenetics and time from diagnosis to transplant
were associated with increased relapse. Reduced intensity conditioning regimen was the only factor associated
with lower non-relapse mortality.
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Conclusions: HSCT was able to rescue about one quarter of the patients with PRF-AML. The donor type did not
have any impact on PRF patients’ outcomes. In contrast, time to transplant was a major prognostic factor for LFS.
For patients with PRF-AML who do not have a matched sibling donor, HSCT from an unrelated donor is a suitable
option, and therefore, initiation of an early search for allocating a suitable donor is indicated.
Keywords: Acute myeloid leukemia, Refractory, Allogeneic stem cell transplantation, HLA-matched related donor,
Unrelated donor, Graft-versus-host disease
Background
Primary refractory acute myeloid leukemia (PRF-AML)
remains a major therapeutic challenge. There is no
agreed definition of PRF-AML, it has been defined by
the absence of complete remission (CR), manifested by
blast count of ≥5% in bone marrow after one or two
cycles of intense induction therapy [1–3]. Recently, less
than a 50% reduction in blast numbers with >15%
residual blasts after one cycle of induction chemotherapy
permits the early identification of patients whose out-
come is very poor [4]. CR is achieved in 10–40% of the
cases depending on the AML patient population. Allo-
geneic stem cell transplantation (HSCT) is the only
salvage option with true curative potential in this sce-
nario [5–8]. In the past decade, the use of reduced
intensity conditioning regimen (RIC) has significantly
increased the proportion of patients with PRF-AML who
are eligible for transplant. Indeed, it has been demon-
strated that HSCT from matched sibling donors (MSD)
is a valid option, leading to disease-free survival rates
that are in the range of 20–30% in these very high risk
devastated patient population [7, 9–11]. More recently,
PRF-AML were offered HSCT from unrelated donors
for (UD), with an overall survival rate (OS) in the range
of 22% [12, 13]. Moreover, HLA mismatch and minor
histocompatibility antigen mismatch, which is assumed
to be present in fully matched unrelated and also in fully
matched related donors, augment donor/recipient alloreac-
tivity, and it has been postulated that histo-incompatibility
between unrelated donors and their recipients may be asso-
ciated with augmented graft-versus-leukemia effect (GVL)
and hence lower risks of relapse [14]. However, the various
studies comparing the outcomes of AML patients with
MSD or UD yielded controversial results, some reporting
inferior survival or disease-free survival with UD HSCT
[15–18], while others concluded to similar survival rates
[19, 20]. One of the largest AML studies reported similar
survival times with MSD and matched UD [21]. Notably,
only small series are available concerning PRF-AML.
Advances in RIC have significantly increased the proportion
of patients with refractory AML who are eligible for trans-
plant. Craddock et al. reported 36 patients who received
transplant with a RIC with an UD with an OS at 36%
at 5 years similar to 18 patients with myeloablative
conditioning regimen (MAC) [12]. In the past decade,
it has been demonstrated that improvement of out-
comes where related to the reduction of non-relapse
mortality (NRM), majority due to lower infections, lower
organ damages, and reduction of severe acute graft-versus-
host disease (aGVHD) [22]. Because the success of UD
HSCT is significantly influenced by the degree of high-
resolution HLA matching [23] and because advances in
supportive care influence outcomes [22, 24, 25], a safety
and efficacy comparison of UD versus MSD HSCT in a
recent and large cohort of patients is highly warranted to
further document decision-making. Therefore, present
study based on the European Society of Blood and Marrow
Transplantation (EBMT)—Acute Leukemia Working Party
(ALWP) database in order to compare outcomes after
MSD HSCT versus 10/10 or 9/10 HLA-matched UD
HSCT for PRF-AML.
Methods
Study design and data retrieval
This is a retrospective, multicenter, registry-based ana-
lysis. Data for this study were provided and approved by
the Acute Leukemia Working Party of the EBMT group
registry. The EBMT registry is a voluntary working group
of more than 600 transplant centers, mostly located in Eur-
ope, that are required to report all consecutive stem-cell
transplantations and follow-up data once a year. Data are
entered, managed, and maintained in a central database
with internet access; each EBMT center is represented in
this database. There are no restrictions on centers for
reporting data, except for those required by the law on
patient consent, data confidentiality, and accuracy. Quality
control measures included several independent systems:
confirmation of validity of the entered data by the reporting
team, selective comparison of the survey data with MED-A
data sets in the EBMT registry database, cross-checking
with the National Registries, and regular in-house and ex-
ternal data audits. Since 1990, patients provide informed
consent authorizing the use of their personal information
for research purposes.
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Eligibility criteria for this analysis included adult
patients (aged >18 years) with PRF-AML in active disease
who had received a first HSCT from HLA-identical sibling
or an unrelated donor (9/10 or 10/10) with bone marrow
or granulocyte colony-stimulating factor-mobilized
peripheral blood stem cells. PRF-AML was defined by
the failure of achieving CR (bone marrow blasts ≤5%)
despite induction chemotherapy. All unrelated donors
were HLA-matched (10/10) or mismatched at one loci
(9/10) (-A, -B, -C, -DRB1, -DQB1). We excluded patients
who had undergone haploidentical or umbilical cord blood
HSCT so that the analysis was restricted to a more homo-
geneous study population. MAC was defined as per EBMT
definition a regimen containing total body irradiation with
a dose >6 Gy, a total dose of oral busulfan (BU) >8 mg/kg,
or a total dose of intravenous BU >6.4 mg/kg [26]. The
sequential strategy consisted of pre-transplant chemother-
apy followed by a conditioning regimen [27]. All patients
provided informed consent for transplants according to the
declaration of Helsinki [26].
End points
OS was calculated from the date of transplant until
death or last observation alive. Leukemia-free survival
(LFS) was calculated from the date of transplant until
relapse or last disease-free follow-up. Relapse and death
from any cause were considered events. NRM was de-
fined as death without prior relapse. Neutrophil recovery
was defined as achieving absolute neutrophil count
greater than—or equal to—0.5 × 109/l for three consecu-
tive days. The diagnosis and grading of acute [28] and
chronic graft-versus-host disease [29] were performed by
transplant centers using the standard criteria. Cytogenetics
abnormalities were classified according to the European
Leukemia Net cytogenetic classification system [30].
Statistical analysis
Patient-, disease-, and transplant-related variables were
compared between the two groups (MSD or UD) using
the chi-square statistic for categorical variables and the
Mann-Whitney test for continuous variables. Variables
considered were patient’s age at transplantation, donor/
recipient sex, interval from diagnosis to transplantation,
cytogenetics group, type of conditioning (RIC/MAC/
FLAMSA), source of stem cells (peripheral blood stem
cell (PBSC) versus bone marrow (BM)), patient/donor
CMV serology, Karnofsky performance status (KPS) at
time of transplantation, in vivo T cell depletion, and year
of transplantation. Factors that differ significantly between
the two groups with p values of <0.05 and all factors known
as potential prognostic factors were included in the final
models. Cumulative incidence functions (CIF) were used to
estimate RI and NRM in a competing risk setting, because
death and relapse compete with each other. To study
chronic graft-versus-host disease (cGVHD), we considered
relapse and death to be competing events. Probabilities of
LFS and OS were calculated using the Kaplan-Meier esti-
mates. Univariate analyses were performed using Gray’s test
for CIF, and the log-rank test for LFS and OS. Associations
of patient and graft characteristics with outcomes were
evaluated in multivariate analysis, using Cox proportional
hazards model. All tests were two-sided. The type-1 error
rate was fixed at 0.05 for determination of factors associ-
ated with time to event outcomes. Statistical analyses were
performed with SPSS 22 (SPSS Inc./IBM, Armonk, NY)
and R 3.2.2 (R Development Core Team, Vienna, Austria)
software packages.
To allow for potential confounding factors between
treatments that could influence outcome, propensity
score matching was also performed, using the nearest
neighbor matching and exact matching for patient age
and cytogenetics group. The following factors were
included in the propensity score model: patient age (less
or more than 50 years), year of transplant, cytogenetics
group, patient and donor CMV serology, female donor
to male recipient vs other combination, time from diag-
nosis to transplant, Karnofsky performance status less or
more than 90% at HSCT, and use of in vivo T cell deple-
tion and conditioning (MAC/RIC/FLAMSA). Owing to
the significant differences in baseline characteristics
between the MSD and UD groups, caliper matching was
fixed to 0.2. The purpose of the propensity score matching
strategy was to reduce confounding effects of these vari-
ables and strengthen causal inferences. Propensity score
analysis was performed using the “MatchIt” (Ref: Package
“MatchIt”. 2015 (accessed: 18 May 2015). http://cran.pro
ject.org/web/packages/MatchIt/MatchIt.pdf). Compari-
sons between the two match-paired groups were stratified
on matching group for taking into account for association
using either mixed effects Cox model.
Results
Patients, disease and transplant characteristics
We obtained data from 211 reporting centers (Additional
file 1), and 104 of whom used both types of donors.
Patient and disease characteristics are summarized in
Table 1. Six hundred sixty patients received a MSD and
381 patients an UD (296 with an HLA-matched 10/10,
and 85 with a mismatched 9/10). The two patient cohorts
were different for several variables (Table 1). The median
year of transplant in the MSD group was 2007 (range
2000–2013), whereas patients with UD underwent HSCT
more recently (median 2010, range 2000–2013; p < 10−5).
Median follow-up for all patients was 39 months (32.5–
47.5) but median follow-up was longer in the MSD group
(48 months [range, 40.1–157.2]) than in the UD group
(30 months [24.7–36.2], p = 0.04). All patients were refrac-
tory in active phase of disease at time of HSCT as per the
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study inclusion criteria. Median age was higher in the UD
group (50.5 years (18–74) vs 47.7 years (18–74) in the
MSD group, p = 0.006). The median time from diagnosis
to HSCT was similar in the two groups (110 days
[60–180] vs 111 days [60–178], respectively, p = 0.33).
In the MSD group, 56.5% received a MAC regimen, 29.2% a
RIC regimen, and 14.3% a sequential conditioning regimen
mainly FLAMSA (fludarabine, cytarabine, and amsacrine)
followed by conditioning regimen, while in the UD group,
44.4% received a MAC regimen, 24.4% a RIC regimen, and
31.2% a sequential conditioning regimen (p < 10−4). The
MSD group contained more cytomegalovirus-positive recip-
ients and recipients with cytomegalovirus-positive donors
than did the UD group (Table 1). Cyclosporine and metho-
trexate were used as the main graft-versus-host disease
prophylaxis in the MSD group. The proportion of patients
who received in vivo T cell depletion significantly differed
between the two groups (34.4% in the MSD group and
80.5% in the UD group, p < 10−5). PBSC was by far the main
stem cell source in both groups (92% in the MSD group vs
94.8% in the UD group, p= 0.09) (Table 1).
Engraftment, GvHD, and response
Cumulative incidence (CI) of neutrophil engraftment
was similar with a MSD and UD, 94.2 and 95.2%, respect-
ively (p = 0.5). Day of absolute neutrophil count ≥500 cells
per μL did not differ as well between HSCT from MSD vs
UD, 15 days (6–43) and 15 days (1–43) days after HSCT,
respectively (p = 0.76) (Table 2).
As expected, lower incidence of all grades aGVHD was
observed post-HSCT with a MSD than a UD; indeed, CI
of grades II–IV were 27.9 and 35.5%, respectively (p =
0.012). However, no difference was observed in the rates
of severe grade III–IV aGVHD (12.3% in the MSD group
and 16.1% in the UD group, (p = 0.09) (Table 2)).
At 2 years, the cumulative incidence of cGVHD was
similar in the two groups (28.9 and 25.8%, respectively,
Table 1 Baseline characteristics of patients
MSD UD p value
Size, n 660 381
Centers, n 199 104
Median follow-up,
months (range)
48 (40.1–157) 30 (27-36) 0.04
Year of Tx (range) 2007 (2000–13) 2010 (2000–13) <10−5
Interval diagnosis to Tx,
day (range)
110 (60–180) 111 (60–178) 0.33
Patient sex, n (%)
Male 393 (59.5) 212 (55.8) 0.24
Female 267 (40.5) 168 (44.2)
Donor sex, n (%)
Male 347 (53) 253 (71) <10−5
Female 308 (47) 103 (29)
Cytogenetics, n (%) 0.02
Good 13 (4.9) 4 (2.9)
intermediate 170 (64.2) 71 (51.8)
Poor 82 (30.9) 62 (45.3)
Unknown/failed 395 244
KPS, n (%)
<90% 183 (29.8%) 119 (33%) 0.30
≥90% 431 (70.2%) 242 (67%)
Female D to male R, n (%)
No 467 (71.3) 306 (86.2) <10−5
Yes 188 (28.7) 49 (13.8)
CMV patient, n (%)
Negative 162 (30.5) 148 (40) 0.003
Positive 369 (69.5) 222 (60)
CMV donor, n (%)
Negative 203 (38.8) 204 (54.4) <10−5
Positive 320 (61.2) 171 (45.6)
Source of stem cell, n (%)
BM 53 (8) 20 0.09
PBSC 607 (92) 361 (94.8)
Conditioning regimen, n (%)
MAC 373 (56.5) 169 (44.4) <10−4
RIC 193 (29.2) 93 (24.4)
Sequential strategy 94 (14.3) 119 (31.2)
In vivo T depletion, n (%)
No 357 (65.6) 73 (19.5) <10−5
Yes 187 (34.4) 302 (80.5)
GVHD prophylaxis, n (%)
CsA alone 85 (12.9) 44 (11.5)
CsA+ MTX 256 (38.8) 93 (24.5)
CsA+ MMF + other 165 (25) 194 (50.9)
Abbreviations: BM bone marrow, CsA cyclosporine, D donor, KPS Karnofsky
Performance Status, MAC myeloablative conditioning regimen, MSD
matched sibling donor, MMF mycophenolate mophetyl, MTX methotrexate,
PBSC peripheral blood stem cell, R recipient, RIC reduced intensity
conditioning regimen, Tx transplantation, UD unrelated donor, GVHD
graft-versus-host disease
Table 2 Transplantation outcomes
MSD (n = 660) UD (n = 381) p value
Engraftment 606 (94.2%) 359 (95.2%) 0.5
Acute GVHD 0.012
Grade 0–I 447 (72.1%) 236 (64.5%)
Grade II–IV 173 (27.9%) 130 (35.5%)
Outcome at 2 years
Leukemia-free survival 25.3% (21.6–28.9) 28.3% (23.3–33.3) 0.56
Overall survival 30.9% (27–34.9) 34.3% (29–39.7) 0.57
Relapse 53.7% (49.6–57.7) 46.4% (40.9–51.7) 0.04
Non-relapse mortality 21% (17.9–24.4) 25.1% (21.7–28.6) 0.11
Chronic GVHD 28.9% (24.9–33) 25.8% (20.8–31) 0.77
Data are n (%) or n (%; 95% CI)
MSD matched sibling donors, UD unrelated donors, GVHD graft-versus-host disease
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p = 0.56) (Table 2). T cell in vivo depletion mostly repre-
sented by ATG was the only favorable factor to prevent
cGVHD (HR= 0.51, 95% CI, 0.35–0.74, p = 0.001) (Table 3).
When investigating the effect of cGVHD on the incidence
of relapse using Cox with time-dependent variables (univar-
iate analysis), we found a significant association between
the two events (HR = 0.60, 95% CI, 0.45–0.81, p = 0.001).
In terms of response, after MSD and UD, 443 patients
(71%) in the MSD group and 247 (69%) patients in the
UD obtained a CR after HSCT, while 148 (24%) and 93
(26%) did not achieved complete remission. Thirty-three
(5.3%) patients in the MSD group and 20 (5.6%) in the
UD group were not evaluable for response because of
early death, respectively (p = 0.73).
LFS, OS, RI, and NRM
In univariate analysis, LFS at 2 years was 25.3% in the
MSD group vs 28.3% in the UD group, respectively
(p = 0.56) (Fig. 1a). In univariate analysis, in intermediate
cytogenetic group, LFS between the two types of donors
MSD and UD was 29.5% (22.5–36.5) and 35.7% (24.2–
47.2) (p = 0.34), respectively In the group with poor cyto-
genetic, LFS at 2 years was 16% (7.5–24.4) in patients
receiving a MSD and 19.8% (9.4–30.1) in patients with an
UD (p = 0.37); OS at 2 years was 21% (11.4–30.7) in the
MSD group and 25.2% (13.9-36.5) in the UD group
(p = 0.89). Multivariate analysis showed lower LFS in pa-
tients who had a poor cytogenetics compared to those
with intermediary risk (HR = 1.61, 95% CI, 1.24–2.09,
p = 0.0004) and when transplant was performed above the
median of 110 days from diagnosis (HR = 1.21, 95% CI,
1.02–1.44, p = 0.03), whereas KPS at transplant ≥90% was
associated with better LFS (HR = 0.67, 95% CI, 0.56–0.80,
p = 0.0001). We noted no effect for donor types, year of
transplant, patient or donor cytomegalovirus (CMV) sta-
tus, in vivo T depletion, and type of conditioning regimen
(Table 3).
OS at 2 years did not differ between the two groups
(30.9% in the MSD group vs 34.3% in the UD group
(p = 0.57)) (Fig. 1b). In univariate analysis, in the inter-
mediate cytogenetic group, OS did not differ statisti-
cally between the two types of donors MSD and UD
(37.1% (29.6–44.5) and 42.6% (30.7–54.4) respectively,
p = 0.226). In the group with poor cytogenetic, OS at
2 years was 21% (11.4–30.7) in the MSD group and
25.2% (13.9–36.5) in the UD group (p = 0.89). OS at
2 years did not statistically differ between the group
with in vivo T cell-depleted graft and no T cell-depleted
graft (p = 0.49) (Additional file 1: Table S1). Looking at the
conditioning regimen, no difference was observed between
MAC, RIC, and sequential strategy (p = 0.602) (Additional
file 1: Table S1). These results were confirmed by multivari-
ate analysis. In multivariate analysis, four predictive factors
were associated with lower OS: age >50 years, cytogenetics
(poor vs intermediate), time from diagnosis to transplant,
and CMV-positive status, whereas KPS at transplant ≥90%
was associated with a better OS (Table 3).
We noted a higher RI in the MSD group compared to
the UD group (53.7 and 46.4%, p = 0.04; respectively)
(Table 2, Fig. 1c). However, in multivariate analysis for
RI, only cytogenetics (poor vs intermediate) and time
from diagnosis to transplant were the only risk factors
associated with increased RI [(HR = 1.74, 95% CI, 1.30–
2.33, p = 0.0002) (HR = 1.29, 95% CI, 1.06–1.58, p = 0.01),
respectively] whereas KPS at transplant was a protective
factor (HR = 0.77, 95% CI, 0.62–0.95, p = 0.01) (Table 3).
No difference in NRM was noted between the two groups
in univariate analysis (Table 2, Fig. 1d). However, multivari-
ate analysis demonstrated that patient age (≥50 years), and
CMV-positive status were associated with higher NRM
(HR = 1.77, 95% CI, 1.27–2.47, p = 0.001; HR = 1.68,
95% CI, 1.14–2.47, p = 0.008), while RIC regimen com-
pared to MAC regimen was the only factor associated
with lower NRM (HR = 0.59, 95% CI, 0.41–0.85, p = 0.005)
(Table 3). We noted no effect for donor types.
Finally, in order to reduce the effects of confounding
factors, we did a propensity score analysis. Using a caliper
of 0.2, we were able to match 221 MSD and 221 UD on
the following variables: patient age (less or more than
50 years), year of transplant, cytogenetics group, patient
and donor CMV serology, female donor to male recipient
versus other combination, time from diagnosis to trans-
plant, Karnofsky performance status less or more than
90% at HSCT, and use of in vivo T cell depletion and con-
ditioning (MAC/RIC/FLAMSA). The results of the Cox
analysis were confirmed in this subpopulation of patients
with balanced characteristics as described in Table 4.
Causes of death
AML was the most common cause of death (64.9% in the
MSD group and 55.3% in the USD group). GVHD repre-
sented 14.2% of death causes in the MSD group and
16.1% in the UD group. Infection was the death cause in
10.8 and 19.4% for the MSD and UD groups, respectively.
Discussion
In the present study, we addressed the topic of HSCT
for patients with PRF-AML a devastating medical condi-
tion with no other therapeutic option for cure. Specifically,
we compared the transplantation outcomes after MSD
versus UD (10/10 or 9/10). Our cohort included 1041 pa-
tients: 660 received MSD HSCT and 381 a UD HSCT
(296 10/10 matched UD HSCT, and 85 9/10 matched
UD). We were able to show about 25% LFS and 30% OS
post-HSCT for this high-risk advanced disease with no
difference between sibling vs unrelated HSCT. Despite
higher rates of grade II–IV aGVHD in the UD group,
neither the 2-year cumulative incidence of severe grade
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III–IV aGVHD, nor cGVHD or the 2-year NRM rates dif-
fered significantly between the two groups (Tables 2 and 3).
Although we could hypothesize a stronger graft-versus-
leukemia effect post UD compared to MSD, we did not ob-
served difference in terms of RI or LFS. Even in the setting
Table 3 Multivariate analysis for LFS, OS, RI, NRM, and cGVHD
HR 95% CI p value
LFS
UD vs MSD 0.96 0.79 1.17 0.68
Age ≥50 years 1.17 0.98 1.40 0.09
Year of Tx >median 1.02 0.85 1.23 0.83
Cytogenetics
Poor vs intermediate 1.61 1.24 2.09 <10−3
Missing vs intermediate 1.18 0.96 1.46 0.11
CMV patient positive 1.19 0.98 1.44 0.09
CMV donor positive 0.99 0.82 1.19 0.90
Female to male 1.03 0.84 1.26 0.77
Diag to Tx > median 1.21 1.02 1.44 0.03
KPS > 90% 0.67 0.56 0.80 <10−5
In vivo T depletion 1.02 0.84 1.26 0.81
Conditioning regimen (ref = MAC)
RIC vs MAC 0.89 0.73 1.08 0.25
Sequential strategy vs MAC 0.91 0.69 1.21 0.53
OS
UD vs MSD 1.02 0.83 1.25 0.87
Age ≥50 years 1.33 1.10 1.61 0.004
Year of Tx >median 1.02 0.84 1.24 0.83
Cytogenetics
Poor vs intermediate 1.55 1.19 2.03 0.001
Missing vs intermediate 1.23 0.99 1.53 0.06
CMV patient positive 1.28 1.04 1.58 0.02
CMV donor positive 0.97 0.80 1.19 0.79
Female to male 1.06 0.86 1.32 0.57
Diag to Tx > median 1.20 1.00 1.44 0.05
KPS >90% 0.65 0.54 0.79 <10−5
In vivo T depletion 0.94 0.76 1.16 0.55
Conditioning regimen (ref = MAC)
RIC vs MAC 0.83 0.67 1.02 0.08
Sequential strategy vs MAC 0.81 0.60 1.09 1.16
RI
UD vs MSD 0.89 0.71 1.12 0.33
Age ≥50 years 0.99 0.80 1.22 0.94
Year of Tx >median 0.95 0.77 1.18 0.66
Cytogenetics
Poor vs intermediate 1.74 1.30 2.33 <10−3
Missing vs intermediate 1.10 0.86 1.40 0.45
CMV patient positive 1.07 0.86 1.33 0.56
CMV donor positive 0.97 0.78 1.20 0.75
Female to male 1.08 0.86 1.37 0.51
Diag to Tx > median 1.29 1.06 1.58 0.01
KPS >90% 0.77 0.62 0.95 0.01
Table 3 Multivariate analysis for LFS, OS, RI, NRM, and cGVHD
(Continued)
In vivo T depletion 1.10 0.87 1.40 0.43
Conditioning regimen (ref = MAC)
RIC vs MAC 1.03 0.81 1.29 0.83
Sequential strategy vs MAC 0.98 0.71 1.35 0.89
NRM
UD vs MSD 1.30 0.91 1.86 0.14
Age ≥50 years 1.77 1.27 2.47 0.001
Year of Tx >median 1.18 0.84 1.64 0.33
Cytogenetics
Poor vs intermediate 1.53 0.91 2.59 0.11
Missing vs intermediate 1.44 0.98 2.13 0.06
CMV patient positive 1.68 1.14 2.47 0.01
CMV donor positive 1.06 0.75 1.49 0.76
Female to male 1.01 0.70 1.47 0.95
Diag to Tx > median 1.06 0.77 1.45 0.72
KPS >90% 0.48 0.35 0.66 <10−5
In vivo T depletion 0.89 0.62 1.29 0.54
Conditioning regimen (ref = MAC)
RIC vs MAC 0.59 0.41 0.85 0.005
Sequential strategy vs MAC 0.82 0.48 1.38 0.45
cGVHD
UD vs MSD 1.22 0.86 1.74 0.26
Age ≥50 years 1.06 0.76 1.47 0.73
Year of Tx >median 1.06 0.76 1.48 0.72
Cytogenetics
Poor vs intermediate 1.01 0.64 1.59 0.96
Missing vs intermediate 0.82 0.58 1.16 0.26
CMV patient positive 1.24 0.87 1.75 0.23
CMV donor positive 1.07 0.76 1.51 0.70
Female to male 1.53 1.07 2.19 0.02
Diag to Tx > median 0.85 0.62 1.17 0.32
KPS >90% 1.01 0.72 1.41 0.97
In vivo T depletion 0.51 0.35 0.74 0.001
Conditioning regimen (ref = MAC)
RIC vs MAC 1.20 0.83 1.73 0.32
Sequential strategy vs MAC 1.07 0.63 1.80 0.81
Abbreviations: CI confidence interval, Diag diagnosis, GVHD graft-vs-host disease,
HR hazard ratio, KPS Karnofsky Performance Status, LFS leukemia-free survival, MAC
myeloablative conditioning, MSDmatched sibling donor, NRM non-relapse mortality,
OS overall survival, RIC reduced intensity conditioning, Tx transplantation,
UD unrelated donor
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of maximum HLA disparity namely haploidentical trans-
plants, we could not observed lower relapse rate as com-
pared to HLA-matched sibling HSCT [20, 31, 32]. One
theoretic explanation is that due to the very aggressive biol-
ogy of the leukemia being refractory to chemotherapy dis-
ease, progression and relapse occur early after transplant as
even the MAC or FLAMSA conditioning are unable to
control the disease while (i) it takes time (up to 9 months)
for the GVL effect to be established and to work against
the leukemia and (ii) in order to be effective, a state of
minimal residual disease or at least substantial reduction in
the leukemic tumoral mass need to be achieved [33, 34].
In our study, 27.5% of patients received a RIC regimen.
As it is PRF, NRM was significantly lower in the RIC
group compared to the MAC group, but there were no
statistically differences in LFS, OS, and RI. This study
had included 213 HSCT patients who received sequential
approach with aplasia-inducing chemotherapy followed by
conditioning regimen. Schmid et al. found a 2-year OS of
40% and a 2-year NRM of 22% using FLAMSA followed by
TBI/cyclophosphamide in patients with refractory AML
who received a MSD or a UD [35]. Stelljes et al. had shown
previously that the 2-year OS with RIC in AML patients in
complete remission versus untreated or refractory disease
from related or unrelated donors is 81 and 21%, respect-
ively [32, 36]. This underlines the potential effect of prior
leukemic burden reduction to improve survival. In the
current study, no outcome differences were found between
MAC, RIC, or sequential regimens. Due to the aggressive
biology of the leukemia and the possible refractoriness to
chemotherapy of the malignant leukemic clone, it is
conceivable that even the most intense chemotherapy
Fig. 1 Probability of a leukemia-free survival (LFS), b overall survival (OS), c relapse incidence (RI), and d non-relapse mortality (NRM) in allografted
patients with PRF-AML
Table 4 Propensity score analysis for LFS, OS, RI, NRM and
cGVHD
MSD UD p value (frailty)
LFS 25.7% (19.1–32.3) 30.1% (23.4–36.8) 0.56
OS 31.3% (24.1–38.6) 38.2% (31.1–45.4) 0.94
RI 54.3% (46.8–61.1) 45.6% (38.3–52.5) 0.11
NRM 20% (14.6–26.1) 24.1% (18.4–30.2) 0.19
cGVHD 24.2% (17.8–31.2) 30.3% (23.4–37.5) 0.08
Abbreviations: cGVHD chronic graft-vs-host disease, LFS leukemia-free survival,
MSD matched sibling donor, NRM non-relapse mortality, OS overall survival,
UD unrelated donor
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conditioning is unable to induce remission or even
transient response which allow sufficient time for the
alloreactive cells to mediate the GVL effect [34]. Future
prospective studies should more specifically address the
outcome differences between these approaches.
Our data identified that proceeding to HSCT as soon
as possible was one of the most important factors determin-
ing the PRF-AML outcome. Indeed, time from diagnosis to
transplant longer than the median (110 days) was a negative
prognostic factor for LFS, OS, and RI in multivariate
analysis. These data are consistent with the study of
Craddock et al. [12] and emphasize the urgent need of
searching for an UD for PRF-AML patients who lack a
matched sibling donor. We may add that this is a factor
we can influence as oppose to most of other factors like
disease biology, cytogenetics, age, and comorbidities.
Thus, we recommend in patients that failed two lines
of therapy not to try additional lines to achieve CR but
to do a fast search and to proceed to transplant.
Cytogenetic features of the AML represent a major
prognostic factor in LFS, RI, and OS [37, 38]. Duval et
al. reported that poor-risk cytogenetics was an adverse
pre-HSCT variable in patients with PRF-AML or re-
lapsed AML and who underwent a MAC regimen [6].
Thereby, PRF-AML with poor cytogenetic characteristics
were associated with statistically significant lower LFS,
higher RI, and lower OS at 2 years in multivariate analysis.
These data pave the road for investigating more intensive
additional approaches relying on sequential conditioning
regimens and/or post-transplant treatments such as 5-
azacytidine, prophylactic donor lymphocytes infusions, or
targeted therapy in order to further improve in the prog-
nosis of this devastating subgroup of patients [39].
Several studies have investigated the prognostic impact
of KPS at transplant [6, 40, 41]. KPS was independently
correlated with toxicities, NRM, and overall mortality
[40]. In our study, KPS at HSCT was of prognostic
value. Indeed, KPS, when stratified into scores of less
than 90% and greater than 90% at HSCT, had a signifi-
cant predictive value for LFS, OS, RI, and NRM. This
simple parameter is a powerful predictor of post-HSCT
outcomes and may therefore contribute to guide our
practical management of PRF-AML.
Being a retrospective study has few limitations: patient
characteristics vary among the groups for several factors in-
cluding year of transplant, age, patient and recipient CMV
status, and cytogenetic risk. There is a relative inherent se-
lection process for HSCT in our study, since the patients
corresponded to a subgroup who fitted the criteria to
undergo HSCT. Also, we do not have information about
why patients were allocated to a specific donor in the regis-
try and distinguishing the choice of the donor from the role
of a potential center effect is difficult. Finally, number of
circulating and bone marrow blasts at time of HSCT are
missing in substantial number of patients. However, the
aim of this analysis was to compare the two types of
donors using EBMT registry data. The design of the
study and inclusion criteria were intended to answer this
clinical question and therefore are not adapted to develop
a prognostic score based on information that is not rou-
tinely collected in the registry. Unfortunately, no ongoing
trials are comparing outcomes after MSD or UD for PRF-
AML. Therefore, in the absence of any prospect of such
comparative studies, our data suggest that both donors
are equally effective in these very high risk patients.
Conclusions
Our results suggest that, when an HLA-identical sibling
donor is not available for an adult with PRF-AML who
is otherwise a candidate for HSCT, a 10/10 or 9/10 UD
may be used with the expectation of similar rates of
NRM, LFS, and OS at 2 years. However, despite this ex-
panded use, as many as one-third of patients will not get
a UD donor source, so that alternative options such as
haploidentical donors and use of cord blood stem cells
may need consideration and evaluation. In these circum-
stances, we would recommend to rather proceed fast to
transplant than multiplying the number of lines of chemo-
therapy that would increase toxicity without achieving an
anti-leukemic response and thus will hamper the chance
to reach HSCT that may rescue about 25% of the patients.
Disease relapse remains the most common cause of treat-
ment failure after HSCT for this group of patients with
PRF-AML. Potential approaches to reduce this high risk
of AML relapse following HSCT could be prophylactic or
preemptive therapy. Few prospective single-arm studies
investigating hypomethylating agents (5-azacytidine or
decitabine) as consolidation therapy for patients with
AML or myelodysplastic syndrome after HSCT have been
published [42–46]. Given the limited number of patients
and the lack of a control arm, a definitive ranking of out-
come results is of course difficult so far but they suggested
a potential benefit impact. Panobinostat, a potent inhibitor
of deacetylases, maintenance post-HSCT was reported to
be feasible and associated with a low relapse rate [47].
Sorafenib maintenance has been recently reported in 27
patients with FTL3-ITD+ with encouraging results [48].
In all, these data suggest that primary refractory AML
patients should be transplanted as quickly as possible
with either a MSD or an UD and maintenance therapy
should be a very promising approach for these very
high risk patients.
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